Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

From marathon gym sessions and trendy detox teas to the latest GLP-1 injections, people will try just about anything to get ...

Trials have confirmed the efficacy of GLP-1 RAs in achieving clinically sustained weight loss in people with obesity without diabetes.

Obesity increases the risk of numerous secondary diseases such as type 2 diabetes, high blood pressure and mental illness. Prof. Dr. Kerstin Stemmer, Professor of Molecular Cell Biology at the ...

A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...